CN105663893A - Junhuang intestinal protection mixture - Google Patents
Junhuang intestinal protection mixture Download PDFInfo
- Publication number
- CN105663893A CN105663893A CN201610057812.9A CN201610057812A CN105663893A CN 105663893 A CN105663893 A CN 105663893A CN 201610057812 A CN201610057812 A CN 201610057812A CN 105663893 A CN105663893 A CN 105663893A
- Authority
- CN
- China
- Prior art keywords
- mass
- taken
- intestinal
- divide
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 50
- 229940079593 drug Drugs 0.000 claims abstract description 28
- 241000894006 Bacteria Species 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000008155 medical solution Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000009636 Huang Qi Substances 0.000 claims description 8
- GYCKQBWUSACYIF-UHFFFAOYSA-N Ethyl salicylate Chemical class CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 5
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 5
- 235000010234 sodium benzoate Nutrition 0.000 claims description 5
- 239000004299 sodium benzoate Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000011282 treatment Methods 0.000 abstract description 26
- 208000031888 Mycoses Diseases 0.000 abstract description 20
- 210000000952 spleen Anatomy 0.000 abstract description 14
- 206010017533 Fungal infection Diseases 0.000 abstract description 11
- 241000721047 Danaus plexippus Species 0.000 abstract description 6
- 208000004880 Polyuria Diseases 0.000 abstract description 6
- 230000035619 diuresis Effects 0.000 abstract description 6
- 210000004072 lung Anatomy 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 239000002671 adjuvant Substances 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 4
- 230000008506 pathogenesis Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract 2
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract 2
- 240000001851 Artemisia dracunculus Species 0.000 abstract 2
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract 2
- 241000045403 Astragalus propinquus Species 0.000 abstract 2
- 241000132012 Atractylodes Species 0.000 abstract 2
- 244000077995 Coix lacryma jobi Species 0.000 abstract 2
- 241000037740 Coptis chinensis Species 0.000 abstract 2
- 235000008599 Poria cocos Nutrition 0.000 abstract 2
- 244000197580 Poria cocos Species 0.000 abstract 2
- 239000001138 artemisia absinthium Substances 0.000 abstract 2
- 235000006533 astragalus Nutrition 0.000 abstract 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 2
- 230000007012 clinical effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- 239000010271 massa medicata fermentata Substances 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 5
- 241000222122 Candida albicans Species 0.000 description 4
- 206010007134 Candida infections Diseases 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 201000003984 candidiasis Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000004232 Enteritis Diseases 0.000 description 3
- 241001363490 Monilia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 201000006306 Cor pulmonale Diseases 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010067268 Post procedural infection Diseases 0.000 description 2
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 2
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000012873 acute gastroenteritis Diseases 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010214 Compression fracture Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061599 Lower limb fracture Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008686 ergosterol biosynthesis Effects 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a Junhuang intestinal protection mixture, relates to a traditional Chinese medicine preparation, in particular to a Junhuang intestinal protection mixture for treating intestinal fungal infection. The Junhuang intestinal protection mixture is characterized in that in terms of the mixture, astragalus membranaceus and heterophylly falsestarwort root are taken as monarch drugs, largehead atractylodes rhizome, poria cocos and coix seeds are taken as ministerial drugs, grassleaf sweelflag rhizome, coptis chinensis and virgate wormwood herb are taken as adjuvant drugs, and medicated leaven is taken as a messenger drug. The Junhuang intestinal protection mixture starts with the lungs and the spleen, the astragalus membranaceus and the heterophylly falsestarwort root are taken as the monarch drugs, the largehead atractylodes rhizome, the poria cocos and the coix seeds are taken as the ministerial drugs, the grassleaf sweelflag rhizome, the coptis chinensis and the virgate wormwood herb are taken as the adjuvant drugs, and the medicated leaven taken as the messenger drug, so that the Junhuang intestinal protection mixture has the functions of invigorating the spleen, replenishing qi, clearing heat and promoting diuresis, carries out treatment for the intestinal fungal infection on the basis of pathogenesis and has better clinical effect.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation, especially a kind of bacterium Huang for treating intestinal canal fungus infection protects intestinal mixture.
Background technology
The rising of deep fungal infections incidence rate, the enteric flora disturbance that antibiotic causes is used to have close relationship with patient's long-term, high-dose, antibiotic side effect is with enteric flora disturbance for starting point, increase with conditionality pathogenic bacterium, bacterial translocation is mark, ultimately causes the infection that case fatality rate is high.
In the especially old patient of danger disease, serious symptom, generally all there are positive QI-insufficiency, the basis that function is low. When owing to there is infectious disease or employing broad ectrum antibiotic or hormone for prophylaxis against infection diseases in this type of patient, it is easily caused internal dysbacteriosis, immunologic function declines further, easily there is fungal infection, but owing to constantly there being the appearance infecting fastbacteria pearl constantly to have new broad ectrum antibiotic to come out, fungal infection still betides danger disease, patient with severe symptoms again and again. Become the difficult point of infectious disease treatment.
At present, western medical treatment intestinal canal fungus infection clinic selects the medicine such as nystatin, fluconazol more, and mildew making usually and has the side effect such as nausea,vomiting,diarrhea, has been reported that adverse reaction rate is up to 15%; Fluconazol is a kind of medicine for the treatment of Systemic fungal infections, for broad-spectrum antifungal medicine, the fungal infection of humans and animals is all had therapeutical effect, has several dosage form of tablet, capsule, injectable powder and injection in the market. Its mechanism of action is mainly the activity of the cytochrome P-450 of high selectivity interference fungus, thus suppressing the biosynthesis of ergosterol on fungal cell membrane, fungal infection is had good therapeutical effect, but its untoward reaction is also comparatively obvious, it is embodied in: 1, common digestive tract reaction, shows as Nausea and vomiting, stomachache or diarrhoea etc.; , occasionally can there is serious exfoliative dermatitis in 2, anaphylaxis: can behave as erythra, often with liver function injury, erythema multiforme exudativu; 3, liver toxicity: slight transient serum amino transferase can be occurred in therapeutic process to raise, occasionally may occur in which liver toxicity symptom, especially easily betides the patient of serious underlying diseases; 4, visible dizziness, headache etc.; 5, some patient, especially has the patient of serious underlying diseases (such as acquired immune deficiency syndrome (AIDS) and cancer), in fact it could happen that the phenomenons such as renal dysfunction. Modern study shows that garlicin is effective to deep fungal infection, but not at the report of wide clinical application. At present, Chinese medicine, in treatment fungal infection especially intestinal canal fungus infection, has scholar to have the report that some Empirical formula are treated, and Chinese patent medicine or hospital preparation is few to intestinal canal fungus infection research report.
Summary of the invention
To be solved by this invention is exactly Western medicine deficiency in treatment intestinal canal fungus infection problem, it is provided that a kind of invigorating the spleen and benefiting QI, clearing away heat-damp and promoting diuresis effect, for treating the determined curative effect of intestinal canal fungus infection, safety, low-cost bacterium Huang guarantor's intestinal mixture.
The bacterium Huang of the present invention protects intestinal mixture, it is characterised in that this mixture, and with the Radix Astragali, Radix Pseudostellariae for monarch drug, the Rhizoma Atractylodis Macrocephalae, Poria, Semen Coicis are ministerial drug, and Rhizoma Acori Graminei, Rhizoma Coptidis and Herba Artemisiae Scopariae are adjuvant drug, and Massa Medicata Fermentata is for making medicine, and is prepared by following steps:
(1) taking 150-450 mass divides the Radix Astragali, 100-300 mass to divide Radix Pseudostellariae, 50-150 mass to divide the Rhizoma Atractylodis Macrocephalae, 75-225 mass to divide Poria, 150-450 mass to divide divert attention song, 50-150 mass of Semen Coicis, 75-225 mass to divide Rhizoma Coptidis, 50-150 mass to divide Herba Artemisiae Scopariae and 50-150 mass to divide Rhizoma Acori Graminei;
(2) putting in container by the medicine of step (1), the water adding weight 4-8 times of weight of parent drugs decocts, and continues to decoct 45-90 minute, be then filtered with 80 mesh sieves, obtain 2800-17500ml filtrate A after solution seethes with excitement;
(3) taking the medicine obtained after filtering in step (2), the water continuously adding weight 2-8 times of weight of parent drugs decocts, and continues to decoct 45-90 minute, be filtered with 80 mesh sieves, obtain 1300-13500ml liquor B after solution seethes with excitement;
(4) liquor B that the filtrate A obtained in step (2) obtains with step (3) is mixed, 1500-10000ml it is concentrated into after mixing, obtain admixing medical solutions, admixing medical solutions adds 1 ‰ sodium benzoate and 0.5 ‰ ethyl hydroxybenzoates, obtain bacterium Huang after uniform stirring and protect intestinal mixture.
The sweet tepor of the Radix Astragali in side, the sweet micro-hardship of Radix Pseudostellariae is put down, and all enters lung, spleen two warp, plays the gas of tonification lung spleen altogether, with strengthening vital QI to eliminate pathogenic factors, is monarch drug altogether; Rhizoma Atractylodis Macrocephalae hardship temperature, replenishing QI to invigorate the spleen dampness, Poria, Semen Coicis are sweet light product, light can eliminating dampness by diuresis, make damp go from urine, reach the use for the treatment of diarrhea by diuretics, the Rhizoma Atractylodis Macrocephalae, Poria, Semen Coicis three strengthen the merit of monarch drug replenishing QI to invigorate the spleen, are ministerial drug altogether; Rhizoma Acori Graminei removing dampness by means of aromatics stomach function regulating, Rhizoma Coptidis heat clearing and damp drying, Herba Artemisiae Scopariae function of gallbladder promoting dehumidifies, spleen preferring dryness to dampness, and along its property for mending, Rhizoma Acori Graminei, Rhizoma Coptidis and Herba Artemisiae Scopariae three assist ministerial drug to dehumidify, and are adjuvant drug altogether; Massa Medicata Fermentata spleen benefiting and stimulating the appetite, and middle antidiarrheal, for making medicine. All medicine compatibilities, have invigorating the spleen and benefiting QI, effect of clearing away heat-damp and promoting diuresis.
Intestinal canal fungus infection patient is many with abdominal pain diarrhea for main clinic symptoms, study carefully have loose bowels because of, do not become what rush down to say with or without wet, so wet institute gives birth to, and relevant to lung splenic function mistake department, the method dried also is started with from lung spleen. Therefore, the bacterium Huang of the present invention is protected intestinal mixture and is just being hited the pathogenesis of intestinal canal fungus infection, therefore clinic can obtain better effects.
Observe emergency department's inpatient, Monilia Enteritis patient totally 60 example, be randomly divided into treatment group and each 30 examples of matched group, wherein:
1, male 22 examples for the treatment of group, female 8 example, 21~88 years old age, average 64.533 ± 13.03 years old; 2~25 days courses for the treatment of, average 7.6 ± 4.87 days, 6.86 ± 3.69 days effective courses for the treatment of; Pulmonary heart disease coronary heart disease 8 example in protopathy, upper gastrointestinal hemorrhage 5 example, acute gastroenteritis 3 example, hypertension and type Ⅱdiabetes mellitus, each 2 examples of gastrointestinal dysfunction, right fracture of tibia and fibula, L3 compression fracture, fl tuberosity fracture, pyogenic cholangitis, pulmonary carcinoma, carcinoma vulvae, myocardial infarction, each 1 example of chronic colitis;
2, matched group man 20 examples, female 10 example, 24~82 years old age, average 65.3 ± 12.37 years old; 2~12 days courses for the treatment of, average 5.9 ± 2.49 days, 5.2 ± 3.57 days effective courses for the treatment of; Pulmonary heart disease upper gastrointestinal hemorrhage 10 example in protopathy, chronic colitis 5 example, hypertensive cardiopathy and each 4 examples of gastrointestinal dysfunction, colon cancer 3 example, acute gastroenteritis and each 2 examples of myocardial infarction;
Two groups there was no significant difference through statistical procedures in age, the course for the treatment of, effective course for the treatment of, therefore have comparability,
Therapeutic Method:
1, treatment group is protected intestinal mixture with bacterium Huang and is treated, and bacterium Huang is protected intestinal mixture and is distributed into 200ml/ bottle, usage: bfore meals, every day three times, each 30ml;
2, matched group uses fluconazol to take orally, 400mgBid on the firstth, later every day 200mg.
Filling in observation table before medication in detail, respectively make routine blood test, liver function and kidney function test once before and after taking, treatment judges curative effect after terminating, and methods of sample collection position intestinal stays fresh stool smear and cultivation.
Criterion of therapeutical effect: 1. recovery from illness: treatment postoperative infection symptom and sign disappear, continuous three the result feminine genders of specimen candidiasis inspection; 2. effective: treatment postoperative infection transference cure, sign is clearly better, and specimen candidiasis checks double feminine gender; 3. effective: after treatment, symptom and sign take a turn for the better, specimen candidiasis inspection is once negative or be still the positive; 4. invalid: after treatment, symptom and sign is without improvement, and specimen candidiasis inspection is still positive.
Comparitive study adopts chi-square criterion, and therapeutic outcome is shown in following table:
As can be seen from the above table, treatment group and matched group curative effect are through statistical procedures P > 0.05, illustrate that said preparation treatment there was no significant difference with fluconazol.
In high spirits turn of patient after treatment group medication, other double diseases have improvement in various degree. Routine blood test change without exception; Serum BUN, Cr, GOT, GPT etc. are normal, and before having few patients's medication, the slight of BUN and Cr raises, and has no and raise after medication. Whole treatment group patient's medication processes have no untoward reaction; After matched group fluconazol, having 15 example patients to see nauseating, 2 examples are shown in headache, and 1 example is shown in stomachache.
Bacterium Huang is protected the acute toxicity testing that intestinal mixture does: the fasting healthy mice of 12 hours 20 before experiment, male and female half and half, intestinal mixture concentrated solution is protected to bacterium Huang by the mice maximum gavage disposable gavage of capacity, dosage is 30g/kg body weight, and animal consumption is equivalent to 133.33 times of people's consumption by kg body weight conversion. The situation observing the aspects such as mouse diet, defecation, activity and hair color for continuous 7 days is raised routinely after administration. The all healthy survival of the whole mice of result, has no overt toxicity reaction. Show oral administration amount safety.
Owing to Monilia Enteritis is that to infect " mould " on the basis of body " weakened body resistance " evil and obtain, and " mould " is evil has heat, poison, wet feature for trouble more, therefore often shows as the card of deficiency in origin and excess in superficiality, simulataneous insufficiency and excessive clinically. For disease feature, in total rule for the treatment of, taking the method for strengthening vital QI to eliminate pathogenic factors, treating both the principal and secondary aspects of a disease, and in conjunction with determining the pathogenesis of ZANG-FU disease based on the differentiation of symptoms and signs, have invigorating the spleen and benefiting QI, the bacterium Huang of clearing away heat-damp and promoting diuresis is protected intestinal mixture and is treated Monilia Enteritis respectively, to reaching the purpose of " vital QI recovered after pathogens eliminated ". According to clinical verification, this mixture truly has good curative effect. Modern study is early it has proven convenient that fungal infection is lowly in close relations with the imbalance of body normal flora and body's immunity.
The bacterium Huang of the present invention protects intestinal mixture, start with from lung spleen, with the Radix Astragali, Radix Pseudostellariae for monarch drug, the Rhizoma Atractylodis Macrocephalae, Poria, Semen Coicis three are ministerial drug, and Rhizoma Acori Graminei, Rhizoma Coptidis and Herba Artemisiae Scopariae three are adjuvant drug, and Massa Medicata Fermentata is for making medicine, there is invigorating the spleen and benefiting QI, effect of clearing away heat-damp and promoting diuresis, the pathogenesis of the intestinal canal fungus infection that hits, clinical effectiveness is better.
Detailed description of the invention
Embodiment 1: a kind of bacterium Huang protects intestinal mixture, is prepared by following steps:
(1) Rhizoma Acori Graminei of the 150g Radix Astragali, 100g Radix Pseudostellariae, the 50g Rhizoma Atractylodis Macrocephalae, 75g Poria, 150g Semen Coicis, 75g Massa Medicata Fermentata, 50g Rhizoma Coptidis, 50g Herba Artemisiae Scopariae and 50g is taken;
(2) medicine of step (1) being amounted to 750g and put in container, the water adding 3000g decocts, and continues to decoct 45-90 minute, be then filtered with 80 mesh sieves, obtain 2800ml filtrate A after solution seethes with excitement;
(3) taking the medicine obtained after filtering in step (2), the water continuously adding 1500g decocts, and continues to decoct 45-90 minute, be filtered with 80 mesh sieves, obtain 1300ml liquor B after solution seethes with excitement;
(4) liquor B that the filtrate A obtained in step (2) obtains with step (3) is mixed, 1500ml it is concentrated into after mixing, obtain admixing medical solutions, admixing medical solutions adds 1 ‰ sodium benzoate and 0.5 ‰ ethyl hydroxybenzoates, obtain bacterium Huang after uniform stirring and protect intestinal mixture.
Embodiment 2: a kind of bacterium Huang protects intestinal mixture, is prepared by following steps:
(1) the 450g Radix Astragali, 300g Radix Pseudostellariae, the 150g Rhizoma Atractylodis Macrocephalae, 225g Poria, 450g Semen Coicis, 225g Massa Medicata Fermentata, 150g Rhizoma Coptidis, 150g Herba Artemisiae Scopariae and 150g Rhizoma Acori Graminei are taken;
(2) medicine of step (1) being amounted to 2250g and put in container, the water adding 18000g decocts, and continues to decoct 45-90 minute, be then filtered with 80 mesh sieves, obtain 17500ml filtrate A after solution seethes with excitement;
(3) taking the medicine obtained after filtering in step (2), the water continuously adding 18000g decocts, and continues to decoct 45-90 minute, be filtered with 80 mesh sieves, obtain 13500ml liquor B after solution seethes with excitement;
(4) liquor B that the filtrate A obtained in step (2) obtains with step (3) is mixed, 10000ml it is concentrated into after mixing, obtain admixing medical solutions, admixing medical solutions adds 1 ‰ sodium benzoate and 0.5 ‰ ethyl hydroxybenzoates, obtain bacterium Huang after uniform stirring and protect intestinal mixture.
Embodiment 3: a kind of bacterium Huang protects intestinal mixture, is prepared by following steps:
(1) the 300g Radix Astragali, 200g Radix Pseudostellariae, the 75g Rhizoma Atractylodis Macrocephalae, 150g Poria, 300g Semen Coicis, 150g Massa Medicata Fermentata, 75g Rhizoma Coptidis, 100g Herba Artemisiae Scopariae and 100g Rhizoma Acori Graminei are taken;
(2) medicine of step (1) is amounted to 1450g and put in container, add 8700g water and decoct, continue to decoct 45-90 minute after solution seethes with excitement, be then filtered with 80 mesh sieves, obtain 8000ml filtrate A;
(3) take the medicine obtained after filtering in step (2), continuously add 8700g water and decoct, continue to decoct 45-90 minute after solution seethes with excitement, be filtered with 80 mesh sieves, obtain 7500ml liquor B;
(4) liquor B that the filtrate A obtained in step (2) obtains with step (3) is mixed, 6000ml it is concentrated into after mixing, obtain admixing medical solutions, admixing medical solutions adds 1 ‰ sodium benzoate and 0.5 ‰ ethyl hydroxybenzoates, obtain bacterium Huang after uniform stirring and protect intestinal mixture.
Claims (1)
1. a bacterium Huang protects intestinal mixture, it is characterised in that this mixture is prepared by following steps:
(1) taking 150-450 mass divides the Radix Astragali, 100-300 mass to divide Radix Pseudostellariae, 50-150 mass to divide the Rhizoma Atractylodis Macrocephalae, 75-225 mass to divide Poria, 150-450 mass to divide divert attention song, 50-150 mass of Semen Coicis, 75-225 mass to divide Rhizoma Coptidis, 50-150 mass to divide Herba Artemisiae Scopariae and 50-150 mass to divide Rhizoma Acori Graminei;
(2) putting in container by the medicine of step (1), the water adding weight 4-8 times of weight of parent drugs decocts, and continues to decoct 45-90 minute, be then filtered with 80 mesh sieves, obtain 2800-17500ml filtrate A after solution seethes with excitement;
(3) taking the medicine obtained after filtering in step (2), the water continuously adding weight 2-8 times of weight of parent drugs decocts, and continues to decoct 45-90 minute, be filtered with 80 mesh sieves, obtain 1300-13500ml liquor B after solution seethes with excitement;
(4) liquor B that the filtrate A obtained in step (2) obtains with step (3) is mixed, 1500-10000ml it is concentrated into after mixing, obtain admixing medical solutions, admixing medical solutions adds 1 ‰ sodium benzoate and 0.5 ‰ ethyl hydroxybenzoates, obtain bacterium Huang after uniform stirring and protect intestinal mixture.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610057812.9A CN105663893A (en) | 2016-01-28 | 2016-01-28 | Junhuang intestinal protection mixture |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610057812.9A CN105663893A (en) | 2016-01-28 | 2016-01-28 | Junhuang intestinal protection mixture |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105663893A true CN105663893A (en) | 2016-06-15 |
Family
ID=56303803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610057812.9A Pending CN105663893A (en) | 2016-01-28 | 2016-01-28 | Junhuang intestinal protection mixture |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105663893A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1130515A (en) * | 1995-03-03 | 1996-09-11 | 李玉魁 | Chinese drug for treating chronic colitis |
CN101259228A (en) * | 2008-04-03 | 2008-09-10 | 刘爱玲 | Compound changning mixture |
-
2016
- 2016-01-28 CN CN201610057812.9A patent/CN105663893A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1130515A (en) * | 1995-03-03 | 1996-09-11 | 李玉魁 | Chinese drug for treating chronic colitis |
CN101259228A (en) * | 2008-04-03 | 2008-09-10 | 刘爱玲 | Compound changning mixture |
Non-Patent Citations (1)
Title |
---|
毕云等: "中药治疗念珠菌性口腔炎、肠炎及肺念珠菌病临床观察", 《实用中医药杂志》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101874874A (en) | Chinese medicinal preparation for treating helicobacter pylori concerned chronic gastritis and preparation method thereof | |
CN104435990B (en) | It is a kind of to promote Chinese medicine composition of abdominal post-operation restoration of gastrointestinal function and preparation method thereof | |
CN102210836A (en) | Application of Chinese medicinal composition in preparation of medicine for treating stomach cancer | |
CN105456897A (en) | Traditional Chinese medicine composition containing argy wormwood leaf for treating spleen deficiency gasterasthenia type chronic gastritis | |
CN102600449A (en) | Traditional Chinese medicine damp-clearing and anti-diarrhea decoction for treating child autumn diarrhea | |
CN104013756A (en) | Traditional Chinese medicine composition for preventing and treating diarrhea and application of traditional Chinese medicine composition | |
CN102488838B (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
CN104225403A (en) | Pharmaceutical composition for treating phthisis as well as preparation method and application thereof | |
CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
CN103110884B (en) | Traditional Chinese medicine composition for treating chronic cholecystitis | |
CN102935177B (en) | Traditional Chinese medicine composition for treating sjogren syndrome as well as preparation method and application thereof | |
CN104225016B (en) | A kind of pharmaceutical composition treating due to weakness of spleen and stomach chronic atrophic gastritis | |
CN105663893A (en) | Junhuang intestinal protection mixture | |
CN102133336B (en) | Traditional Chinese medicine composite, and preparation method and application thereof | |
CN103156961B (en) | Medicine composition used for treating common cold, wind cold, and lung and stomach heat stagnation | |
CN101947299B (en) | Medicinal composition for treating coronary heart disease | |
CN105267372A (en) | Traditional Chinese medicine granule for treating postoperative gastrointestinal dysfunction and its preparation method | |
CN101579496B (en) | Application of Chinese medicine composition in preparation of medicine for treating atypical hyperplasia of gastric mucosa | |
CN102688254B (en) | Medicinal composition for treating chronic diarrhea and preparation method and use thereof | |
CN101637533B (en) | Application of Chinese medicinal composition in preparation of medicament for treating virus myocarditis | |
CN1981812B (en) | Chinese-medicinal preparation for treating AIDS and its production | |
CN107213323B (en) | Chinese medicinal compound preparation for nourishing yin, eliminating phlegm, resolving masses and detoxifying and application thereof | |
CN105663899A (en) | Traditional Chinese medicine preparation for treating pulmonary abscess | |
CN105521370A (en) | Pharmaceutical preparation for treating colon cancer and application thereof | |
CN105030887A (en) | Traditional Chinese medicine preparation for treating infantile diarrhea with damp-heat syndrome and its preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160615 |